RCUS (STOCKS)
Arcus Biosciences, Inc.
$24.180000
+0.380000 (+1.60%)
Prev close: $23.800000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Terry J. Rosen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,039.94M
- Employees
- 674
- P/E (TTM)
- -7.48
- P/B (TTM)
- 5.70
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.02 | $-0.89 | -0.1256 | -14.04% |
|
Dec 2025 (Q4)
|
$-0.89 | $-1.05 | +0.1567 | +14.97% |
|
Sep 2025 (Q3)
|
$-1.27 | $-1.34 | +0.0662 | +4.95% |
|
Jun 2025 (Q2)
|
$0.00 | $-1.15 | +1.1492 | +100.00% |
Financial Statements
| Revenues | $236.00M |
| Benefits Costs and Expenses | $445.00M |
| Costs And Expenses | $613.00M |
| Nonoperating Income/Loss | $29.00M |
| Operating Expenses | $634.00M |
| Depreciation and Amortization | $9.00M |
| Research and Development | $523.00M |
| Other Operating Expenses | $106.00M |
| Operating Income/Loss | -$398.00M |
| Income/Loss From Continuing Operations After Tax | -$209.00M |
| Income/Loss From Continuing Operations Before Tax | -$209.00M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$369.00M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$369.00M |
| Net Income/Loss Available To Common Stockholders, Basic | -$369.00M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$3.19 |
| Diluted Earnings Per Share | -$3.19 |
| Basic Average Shares | 341,700,000 |
| Diluted Average Shares | 342,100,000 |
| Assets | $997.00M |
| Current Assets | $844.00M |
| Noncurrent Assets | $153.00M |
| Fixed Assets | $38.00M |
| Other Non-current Assets | $115.00M |
| Liabilities | $473.00M |
| Current Liabilities | $209.00M |
| Accounts Payable | $39.00M |
| Wages | $19.00M |
| Other Current Liabilities | $151.00M |
| Noncurrent Liabilities | $264.00M |
| Long-term Debt | $100.00M |
| Other Non-current Liabilities | $164.00M |
| Equity | $524.00M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $524.00M |
| Liabilities And Equity | $997.00M |
| Net Cash Flow From Operating Activities | -$488.00M |
| Net Cash Flow From Operating Activities, Continuing | -$488.00M |
| Net Cash Flow From Investing Activities | $148.00M |
| Net Cash Flow From Investing Activities, Continuing | $148.00M |
| Net Cash Flow From Financing Activities | $349.00M |
| Net Cash Flow From Financing Activities, Continuing | $349.00M |
| Net Cash Flow | $9.00M |
| Net Cash Flow, Continuing | $9.00M |
| Comprehensive Income/Loss | -$370.00M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$370.00M |
| Other Comprehensive Income/Loss | -$1.00M |
| Other Comprehensive Income/Loss Attributable To Parent | -$1.00M |